Active Biotech and NeoTX enter into a partnership for the development and commercialization of ANYARA for immuno-oncology
October 26 2016 - 2:35AM
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) and NeoTX Therapeutics
Ltd. announced today that they have entered into a licensing
agreement for Active Biotech's investigational compound
Naptomumab estafenatox ("ANYARA") for cancer
immunotherapy. NeoTX will be responsible for the worldwide
clinical development and commercialization of the drug. This
partnership is a key milestone in NeoTX's strategy to bring tumor
recognition enhancing therapeutics to the market. "We are very
enthusiastic about our collaboration with Active Biotech. At
NeoTX, we are strongly committed to developing innovative
immunotherapies for unmet medical needs. "Active Biotech brings to
our collaboration outstanding scientific and intellectual capital,
and a powerful commitment to positively impact the treatment of
cancer," said
Asher Nathan, Chief Executive Officer of
NeoTX. Dr. Marcel Rozencweig, Chief Medical Officer of
NeoTX and former Head of Global Clinical Oncology Research at
BMS said "We are looking forward to developing ANYARA for
immuno-oncology applications. We believe that the ANYARA technology
is well suited to increase tumor recognition by the immune system
and has demonstrated synergistic activity in combination with
checkpoint inhibitors in animal models. As such, ANYARA would be
attractive in combination with checkpoint inhibitors whose efficacy
can be limited by poor tumor recognition". "We are excited
about the partnership with NeoTX, who we consider as an ideal
partner for ANYARA. This partnership constitutes the next step in
the clinical development, as well as the commercialization
strategy, for the project." said
Tomas Leanderson, President
& CEO of Active Biotech. About the agreement
Under the terms of the agreement, Active Biotech grants NeoTX
exclusive rights to develop and commercialize ANYARA worldwide in
cancer indications. The total deal value amounts to $71 million and
is contingent upon achievement of clinical, regulatory and
commercial milestones whereof Active Biotech will receive $250 000
as an initial payment upon signing. In addition, NeoTX will
pay Active Biotech progressive, double-digit royalties on its net
sales.
About ANYARA ANYARA is a TTS (Tumor Targeting
Superantigen) compound that increases the ability of the immune
system to recognize the tumor. Synergy has been reported in vivo
with a combination of ANYARA and a checkpoint inhibitor in an
experimental tumor model. Clinically, the development of ANYARA has
primarily been focused on cancer indications with a high unmet
medical need. Positive data was reported from clinical Phase I
trials in lung cancer, renal cell cancer and pancreatic cancer,
where ANYARA was studied both as a single agent (monotherapy) and
in combination with an established tumor therapy - docetaxel
(Taxotere®) - in patients with advanced cancer. The results showed
that ANYARA was well tolerated both as monotherapy and in
combination with docetaxel, and increased tumor recognition by T
cells. A Phase 2/3 trial of ANYARA in combination with interferon
alpha in renal cell cancer demonstrated acceptable safety but did
not meet its primary efficacy endpoint in the ITT population. The
upcoming clinical trial will be done in combination with drugs that
inhibit checkpoint dampening of the immune system, a combination
strategy in line with the mode of action of ANYARA and supported by
preclinical data.
NeoTX Therapeutics Ltd. is based in Rehovot Israel and is
a clinical stage immuno-oncology company. NeoTX was founded to
bring safe and effective immunotherapies to cancer patients. Please
visit www.neotx.com for more information.
Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) is a
biotechnology company with focus on neurodegenerative/inflammatory
diseases and cancer. Laquinimod, an orally administered small
molecule with unique immunomodulatory properties, is in pivotal
Phase 3 development for the treatment of relapsing remitting
multiple sclerosis. Also, laquinimod is in Phase 2 development for
the treatment of primary progressive multiple sclerosis and
Huntington's disease. Furthermore, commercial activities are
conducted for the tasquinimod, paquinimod and SILC projects. Please
visit www.activebiotech.com for more information.
For further
information, please contact: Asher Nathan CEO Tel: +1 609 718
2305 x 1 Robert Harow, CFO Tel: +1 609 718 2305 x 2 |
NeoTX Therapeutics Ltd.
(Corp.Reg. No. 515220929) 2 Pekeris Street Rehovot, Israel Tel: +1
609 718 2305 Tel: +972 3 912 5853 |
Tomas Leanderson,
President and CEO Tel: +46 46 19 20 95 Hans Kolam, CFO Tel: +46 46
19 20 44 |
Active Biotech AB (Corp.
Reg. No. 556223-9227) Box 724, SE-220 07 Lund, Sweden Tel: +46 46
19 20 00 |
This information is information that Active Biotech AB is
obliged to make public pursuant to the EU Market Abuse Regulation.
The information was submitted for publication, through the agency
of the contact person set out above, at 08.30 am CET on October 26,
2016.
20161026_Active Biotech_NeoTX_
http://hugin.info/1002/R/2050859/767387.pdf
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Apr 2023 to Apr 2024